Key result
Novel antiplatelet agents targeting new receptors and signaling pathways have yielded promising results in preclinical and early clinical studies for cardiovascular disease.
Why the study?
Established antiplatelet agents significantly increase bleeding risk and atherothrombotic events still occur, prompting the development of new agents targeting novel platelet pathways.
Novel antiplatelet agents targeting newly discovered pathways may offer high antithrombotic efficacy with potentially lower bleeding risks compared to established therapies.
receptor antagonists, glycoprotein IIb/IIIa inhibitors, and the thrombin receptor blocker vorapaxar are effective antiplatelet agents but significantly increase the risk of bleeding. Moreover, atherothrombotic events still impair the prognosis of many patients with cardiovascular disease despite established antiplatelet therapy. Over the last years, advances in the understanding of thrombus formation and hemostasis led to the discovery of various new receptors and signaling pathways of platelet activation. As a consequence, many new antiplatelet agents with high antithrombotic efficacy and supposedly only moderate effects on regular hemostasis have been developed and yielded promising results in preclinical and early clinical studies. Although their long journey from animal studies to randomized clinical trials and finally administration in daily clinical routine has just begun, some of the new agents may in the future become meaningful additions to the pharmacological armamentarium in cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Tscharre et al. (2020) conducted a review in Cardiovascular disease. Novel antiplatelet agents was evaluated. Novel antiplatelet agents targeting new receptors and signaling pathways have yielded promising results in preclinical and early clinical studies for cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: